Paul Mead - Implantica Chief Officer
| IMP-A-SDB | SEK 35.05 1.40 3.84% |
Insider
Paul Mead is Chief Officer of Implantica AG
| Age | 45 |
| Phone | 41 41 539 19 02 |
| Web | https://www.implantica.com |
Implantica Management Efficiency
The company has return on total asset (ROA) of (0.0674) % which means that it has lost $0.0674 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.147) %, meaning that it generated substantial loss on money invested by shareholders. Implantica's management efficiency ratios could be used to measure how well Implantica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Adv | Surgical Science Sweden | 55 | |
| Martin Jonassen | Storytel AB | 46 | |
| Mark Pasternak | Storytel AB | 45 | |
| AnnMarie Thor | Bonesupport Holding AB | N/A | |
| Jonas Tellander | Storytel AB | 53 | |
| Gisli Hennermark | Surgical Science Sweden | 51 | |
| Sofie Zettergren | Storytel AB | 37 | |
| Michael Roth | Bonesupport Holding AB | 60 | |
| Inbal MazorBadichi | Surgical Science Sweden | 54 | |
| Dan Panas | Storytel AB | 55 | |
| Jeffrey Berkley | Surgical Science Sweden | 54 | |
| Doron Zilberman | Surgical Science Sweden | 61 | |
| Daniel Evestedt | Surgical Science Sweden | 46 | |
| Ran Bronstein | Surgical Science Sweden | 59 | |
| Andreas Lindblom | Storytel AB | N/A | |
| Anders Larsson | Surgical Science Sweden | 50 | |
| Fergus MacLeod | Bonesupport Holding AB | 53 | |
| Johannes Larcher | Storytel AB | 56 | |
| Michael MD | Bonesupport Holding AB | 49 | |
| Claus WamslerNielsen | Storytel AB | 48 | |
| Emil Billbck | Bonesupport Holding AB | 53 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0674 |
Implantica AG Leadership Team
Elected by the shareholders, the Implantica's board of directors comprises two types of representatives: Implantica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Implantica. The board's role is to monitor Implantica's management team and ensure that shareholders' interests are well served. Implantica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Implantica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephan Siegenthaler, Chief Member | ||
| Nicole Pehrsson, Chief Officer | ||
| Andreas hrnberg, Chief Officer | ||
| Paul Mead, Chief Officer | ||
| Stefan Vogt, Chief Officer | ||
| Steffen Schanz, VP Management | ||
| Amit Kukreja, Chief Officer | ||
| Jrg MangerKoenig, Company Board | ||
| Peter Forsell, Founder CEO |
Implantica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Implantica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0674 | |||
| Operating Margin | (24.51) % | |||
| Current Valuation | 5.38 B | |||
| Shares Owned By Institutions | 28.58 % | |||
| Revenue | 707 K | |||
| Gross Profit | (867 K) | |||
| EBITDA | (17.06 M) | |||
| Net Income | (15.36 M) | |||
| Cash And Equivalents | 147.29 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Implantica Stock Analysis
When running Implantica's price analysis, check to measure Implantica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Implantica is operating at the current time. Most of Implantica's value examination focuses on studying past and present price action to predict the probability of Implantica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Implantica's price. Additionally, you may evaluate how the addition of Implantica to your portfolios can decrease your overall portfolio volatility.